We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Trastuzumab Deruxtecan for the Treatment of HER2-low Advanced or Metastatic Breast Cancer.
- Authors
Toshinari Yamashita
- Abstract
T rastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate widely used in human epidermal growth factor receptor 2 (HER2)- positive metastatic breast cancer (MBC), based on the results of the DESTINY-Breast 01, 02 and 03 studies. The data show the efficacy of T-DXd in HER2-low (defined as HER2 expression of 1+, 2+ and ISH [in situ hybridization]-) breast cancer. The DESTINY-Breast04 trial, a randomized trial comparing T-DXd with the treatment of physician’s choice (TPC) in pretreated MBC with low HER2 expression, showed higher efficacy for T-DXd than for TPC. Because of its landmark results, the DESTINY-Breast04 trial was simultaneously published in the New England Journal of Medicine when presented at the 2022 American Society of Clinical Oncology Annual Meeting. T-DXd is now being used for HER2-low-expressing breast cancer as the second-line treatment and beyond. The DESTINY-Breast06 trial, which evaluated the efficacy of T-DXd as the first-line treatment, has completed the enrolment and is awaiting results. This article reviews the findings on T-DXd in advanced recurrent breast cancer with low HER2 expression.
- Subjects
NEW England; METASTATIC breast cancer; AMERICAN Society of Clinical Oncology; EPIDERMAL growth factor receptors; ANTIBODY-drug conjugates; TRASTUZUMAB; BREAST cancer
- Publication
touchREVIEWS in Oncology & Haematology, 2024, Vol 20, Issue 1, p36
- ISSN
2752-5481
- Publication type
Article